Overview
A. RP Management, LLC (also referred to as “we”, “us”, the “firm” and “RPM”),
founded in 2003, is an investment services firm specializing in investment
management for its clients. Its clients, including private funds and a public limited
company incorporated under the laws of England and Wales (the “Clients”),
indirectly own portions of subsidiaries holding royalty interests through their
interests in one of two vehicles—(A) Royalty Pharma Investments (“RPI”), an Irish
Unit Trust (the “Unit Trust”) or (B) Royalty Pharma Investments 2019 ICAV, an
Irish Collective Asset-management Vehicle (the “ICAV”). The principal owners of
our firm are Pablo Legorreta and RP MIP Holdings LLC. Investors in our Clients
are referred to herein as “Investors”.
B. RPM specializes in advising on investments in royalty interests in marketed and
development-stage pharmaceutical, biopharmaceutical, medical and/or healthcare
products.
C. Our firm tailors our advisory services to the individual needs and specified
investment mandates of our Clients. We adhere to the investment strategy set forth
in the prospectuses of the Clients and the relevant investment management
agreements.
D. We do not participate in wrap fee programs.
The amount of Client assets that we manage on a discretionary basis, as of
December 31, 2023, measured in the same manner as our regulatory assets under
management, was approximately $17,646,826,055.
We do not manage any Client assets on a non-discretionary basis.